Dividend logo

Gilead Sciences, Inc. (GILD ) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The company’s primary areas of focus are immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) and chronic hepatitis B virus (HBV), oncology and inflammation, and serious cardiovascular and respiratory conditions. The company has two high-profile treatments: Harvoni and Sovaldi. These two drugs accounted for nearly 60% of the company’s revenue in both quarters of 2015.

Additionally, Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands approximately 75% of the U.S. treatment market and more than 50% worldwide.

Gilead Sciences recently started paying a quarterly dividend of $0.43 per share. Its first payout was on 6/29/2015. It’s going Ex-Dividend again on 9/14/2015. Its annual payout comes to $1.72, yielding 1.50% on its current price of $114.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Market%20performance%20charts
News

The Market Wrap For January 18: A Critical Earnings Season Begins

It’s no secret that the market’s direction has all been news-driven. The news about the trade...

News

Trending: Vodafone Dividend at Risk as Challenges Mount

Dividend.com analyzes the search patterns of our visitors each week. By sharing these trends with...

Premium Value%20stocks
News

Value Stocks Are Dirt Cheap & That’s Wonderful News For Dividend Investors

Pull up any broad chart and you’ll notice one thing. That is, the markets have been focused on ‘...